New medicine prices in the EU have risen over the past few decades, to the point of being unaffordable for many EU citizens and threatening the sustainability of national health care systems, say MEPs in a resolution voted on Thursday. To strike a better balance between EU countries’ public health interests and those of the pharmaceutical industry, it calls for measures to improve the traceability of R&D costs, public funding and marketing expenditure. Read more.
26th February 2018
9th March 2018